CAS: 20662-53-7; 3-Piperidin-4-Yl-1H-Benzimidazol-2-One

上下游产品

CAS号87120-81-8 4-(2-氧代-2,3-二氢-... | CAS号173843-48-6 4-(3-甲基-2-氧代-2,... | CAS号85443-52-3 ethyl 4-[(2-nit... | CAS号58859-46-4 4-氨基-1-哌啶甲酸乙酯 | CAS号53786-47-3 ethyl 4-(2,3-di... | CAS号87120-77-2 ethyl 4-(2-amin... | CAS号79099-07-3 1-B°C-4-哌啶酮 | CAS号95-54-5 邻苯二胺(OPD) | CAS号79099-00-6 4-(2-氨基苯氨基)哌啶-1... | CAS号2062-78-4 匹莫齐特 | CAS号86015-38-5 3-[1-[3-(6-fluo... | CAS号87120-81-8 4-(2-氧代-2,3-二氢-... | CAS号612847-29-7 3-(4-{[4-(2-Oxo... | CAS号612848-74-5 1-(4-((4-(2-OXO... | CAS号634616-95-8 TBPB | CAS号6441-58-3 N-[(4-ethylphen...

2,3-二氟硝基苯置于碳酸氢钠,Potassium Carbonate,三氟乙酸体系中,化学反应生成4-(2-酮酸-1-苯并咪唑)哌啶
参考文献:Heterocyclic Compound,Application Thereof,And Composition Containing Same
标题:Heterocyclic Compound,Application Thereof,And Composition Containing Same
摘要:由式xi表示的杂环化合物,其药用盐,溶剂合物,或其药用盐的溶剂合物,以及其用途和含有该化合物的组合物.该化合物在结构上是新颖的,并具有非常好的stat5抑制活性.

专利信息

专利号:US-6906046-B2
优先权日:2000-12-22
标题 :Pharmaceutical uses and synthesis of benzobicyclooctanes
发明人：JACKSON RANDY W; DARWISH IHAB; BAUGHMAN TED A; HOWBERT J JEFFRY
权利人:CELLTECH R & D INC
摘要:Benzobicyclooctane compounds, their use in inhibiting cellular events involving TNF-α and IL-8, and in the treatment of inflammation events in general; a combinatorial library of diverse bicyclooctanes and process for their synthesis as a library and as individual compounds.

专利号:US-7186709-B2
优先权日:2002-08-27
标 题:Dihydropyrancarboxamides and uses thereof
发明人：SCHREIBER STUART L; STAVENGER ROBERT A; MITCHISON TIMOTHY J; MALIGA ZOLTAN
权利人:HARVARD COLLEGE
摘要:The present invention provides novel dihydropyrancarboxamide compounds of formula (I): n nand collections of these compounds, and provides methods for the synthesis of these compounds; wherein R 1 –R 6 are as defined herein. Additionally, the present invention provides pharmaceutical compositions and methods for treating disorders such as proliferative diseases, and cancer, to name a few.

专利号:US-6326372-B1
优先权日:1999-09-30
标 题:Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
发明人：EVANS BEN E; GILBERT KEVIN F
权利人:MERCK & CO INC
摘要:Lactam and cyclic urea derivatives and their pharmaceutically acceptable salts are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are typically selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

专利号:US-7829699-B2
优先权日:2006-04-10
标题:Process for the preparation of CGRP antagonist
发明人：BELYK KEVIN; RIVERA NELO
权利人:MERCK SHARP & DOHME
摘要:An efficient synthesis for the preparation of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1 -carboxamide, by coupling (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one and 2-oxo-1-(4-piperidinyl)-2,3-dihydro-1H-imidazo[4,5-b]pyridine dihydrochloride with 1,1′-carbonyldiimidazole (“CDIâ€?) as carbonyl source; and an efficient preparation of the potassium salt of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide.

专利号:US-2003069305-A1
优先权日:2000-12-22
标题:Pharmaceutical uses and synthesis of benzobicyclooctanes

专利号:US-6096763-A
优先权日:1995-02-23
标题 :α1a adrenergic receptor antagonists
发明人：HOFFMAN JACOB M; CHANG RAYMOND S L
权利人:MERCK & CO INC
摘要:This invention relates to novel compounds, their synthesis and use as selective α 1a adrenergic receptor antagonists. One application of the compounds is in the treatment of benign prostatic hyperplasia. The compounds are selective in their ability to relax smooth muscle tissue enriched in the α 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.